Bristol-Myers Squibb Company
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0R1F.IL | BIIB | ABBV | AMGN | LLY | PFE | |
|---|---|---|---|---|---|---|
| Market cap | 131.89B | 37.02B | 503.46B | 239.22B | 1.14T | 171.36B |
| P/E (TTM) | 16.5 | 44.5 | 80.5 | 27.5 | 43.0 | 39.6 |
| Forward P/E | — | 15.2 | 17.6 | 18.1 | 27.1 | 10.4 |
| Price/book | 4.0 | 2.0 | -84.8 | 20.5 | 33.7 | 2.0 |
| Dividend yield | 4.04% | — | 2.43% | 2.25% | 0.53% | 5.65% |
| 1-year change | +37.70% | +69.35% | +25.09% | +53.30% | +58.30% | +22.86% |
| Today | −0.16% | −1.30% | −0.10% | −1.07% | −1.97% | −1.17% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All 0R1F.IL news ›Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
It recently received accelerated FDA approval for its multiple myeloma treatment Zenbexus, and it announced a $2.3 billion investment to build a new manufacturing campus in Texas. Pfizer (PFE +1.91%) primarily generates revenue by…
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility
During the most recent period, it announced a multibillion-dollar financial investment to establish a multimodal manufacturing campus located in Texas, while also securing an accelerated regulatory approval from the FDA for a combination…
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
It recently secured expanded regulatory approvals from the U.S. Food and Drug Administration for its targeted cardiovascular treatments, and it separately entered a strategic partnership with Nvidia to deploy advanced artificial…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY). Wells Fargo analyst Mohit Bansal assigned a Buy rating to…
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?
It completed the acquisition of Apogee Therapeutics to expand its dermatology and respiratory pipeline, and it secured regulatory approvals for multiple therapies in international markets. It secured accelerated regulatory approval for a…
Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
(NYSE:BMY) Seeking Alpha - On October 27, Bristol-Myers Squibb will report its results for Q3. - As a reminder, its Q2 revenue rose 12.9% quarter-on-quarter to $12.97 billion, primarily due to the strong performance of Camzyos and the…
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?
For questions about this article or underlying research, email [email protected]. Why Are Bristol Myers Squibb’s Eliquis Sales Still Rising? Eliquis sales rose 21% in fiscal Q2 2026. On the July 30 call, management said strong demand and…
Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%
Moderna shares are surging ahead of a closely watched cancer data presentation in Madrid, but the company's razor-thin revenue base means a single readout could swing the stock sharply in either direction. Moderna‘s (NASDAQ:MRNA | MRNA…
What Is Going On With Bristol Myers Squibb Stock?
Bristol Myers Squibb (BMY) stock trades at 12.9 times earnings, compared with 22.7 for the median S&P 500 company. That is a low price for a drugmaker that widened its profit margin over the past year, even after the stock returned 41.6%…
Better Dividend Stock: Merck vs. Bristol Myers Squibb
Pressmaster from Pressmaster and Ri_Ya from pixabay Merck (MRK) and Bristol Myers Squibb (BMY) both raised their 2026 sales outlooks this summer. That’s good news for income investors, since a growing business keeps a dividend growing. The…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
theglobeandmail.com21
-
marketscreener.com20
-
fool.com13
-
marketbeat.com11
-
gurufocus.com9
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.